PDL Biopharma (PDLI) 8-K PDL BioPharma Provides Fourth Quarter 2013 Revenue Guidance of $109 Million

Exhibit 99.2

Royalty Revenue by Product ($ in 000's) *
Avastin	Q1	Q2	Q3	Q4	Total
2013	33,234	46,720	32,224	32,287	144,464
2012	23,215	41,670	25,955	30,041	120,882
2011	22,283	41,967	23,870	22,886	111,006
2010	16,870	44,765	29,989	24,922	116,547
2009	13,605	35,161	21,060	15,141	84,966
2008	9,957	30,480	19,574	12,394	72,405
2007	8,990	21,842	17,478	9,549	57,859
2006	10,438	15,572	15,405	12,536	53,952
Herceptin	Q1	Q2	Q3	Q4	Total
2013	30,287	47,353	30,961	33,038	141,640
2012	25,702	44,628	30,433	28,307	129,070
2011	25,089	42,209	31,933	21,812	121,042
2010	23,402	38,555	27,952	25,441	115,350
2009	16,003	32,331	26,830	18,615	93,779
2008	14,092	34,383	28,122	20,282	96,880
2007	19,035	28,188	22,582	14,802	84,608
2006	15,142	19,716	21,557	20,354	76,769
Lucentis	Q1	Q2	Q3	Q4	Total
2013	12,032	30,066	13,536	12,127	67,760
2012	10,791	27,938	12,552	11,097	62,377
2011	8,878	24,313	12,157	10,750	56,099
2010	7,220	19,091	10,841	8,047	45,198
2009	4,621	12,863	8,123	6,152	31,759
2008	3,636	11,060	7,631	4,549	26,876
2007	2,931	6,543	6,579	3,517	19,570
2006	—	—	289	3,335	3,624
Xolair	Q1	Q2	Q3	Q4	Total
2013	5,930	10,025	7,334	7,330	30,619
2012	5,447	8,609	6,504	6,145	26,705
2011	4,590	7,621	5,916	5,823	23,949
2010	3,723	6,386	4,980	4,652	19,741
2009	2,665	5,082	4,085	3,722	15,553
2008	1,488	4,866	3,569	2,927	12,850
2007	1,684	3,942	3,332	2,184	11,142
2006	2,263	2,969	3,041	2,495	10,768
Perjeta	Q1	Q2	Q3	Q4	Total
2013	340	1,414	748	879	3,381
2012	—	—	58	250	308
2011	—	—	—	—	—
2010	—	—	—	—	—
2009	—	—	—	—	—
2008	—	—	—	—	—
2007	—	—	—	—	—
2006	—	—	—	—	—
Kadcyla	Q1	Q2	Q3	Q4	Total
2013	—	551	830	859	2,240
2012	—	—	—	—	—
2011	—	—	—	—	—
2010	—	—	—	—	—
2009	—	—	—	—	—
2008	—	—	—	—	—
2007	—	—	—	—	—
2006	—	—	—	—	—
Tysabri	Q1	Q2	Q3	Q4	Total
2013	12,965	13,616	11,622	12,100	50,304
2012	11,233	12,202	11,749	12,255	47,439
2011	9,891	10,796	11,588	11,450	43,725
2010	8,791	8,788	8,735	9,440	35,754
2009	6,656	7,050	7,642	8,564	29,912
2008	3,883	5,042	5,949	6,992	21,866
2007	839	1,611	2,084	2,836	7,370
2006	—	—	—	237	237
Actemra	Q1	Q2	Q3	Q4	Total
2013	2,631	2,816	2,939	3,744	12,131
2012	1,705	2,074	2,145	2,462	8,385
2011	913	1,136	1,401	1,460	4,910
2010	1,587	237	315	688	2,827
2009	585	537	909	1,197	3,228
2008	44	—	146	369	559
2007	32	—	—	17	49
2006	—	—	—	—	—
* As reported to PDL by its licensees
Totals may not sum due to rounding

Reported Net Sales Revenue by Product ($ in 000's) *
Avastin	Q1	Q2	Q3	Q4	Total
2013	1,653,108	1,694,678	1,746,135	1,819,877	6,913,798
2012	1,502,757	1,573,727	1,551,327	1,662,977	6,290,788
2011	1,597,461	1,582,705	1,581,095	1,469,994	6,231,255
2010	1,506,788	1,596,892	1,594,707	1,646,218	6,344,605
2009	1,345,487	1,295,536	1,439,730	1,514,053	5,594,806
2008	980,715	1,084,930	1,180,427	1,239,382	4,485,454
2007	678,068	746,587	797,013	875,084	3,096,752
2006	439,318	516,052	570,551	592,897	2,118,817
Herceptin	Q1	Q2	Q3	Q4	Total
2013	1,681,574	1,744,145	1,681,860	1,726,551	6,834,130
2012	1,515,255	1,625,313	1,663,695	1,650,495	6,454,759
2011	1,391,568	1,559,975	1,642,898	1,432,771	6,027,211
2010	1,270,846	1,349,512	1,300,934	1,409,310	5,330,602
2009	1,210,268	1,133,993	1,226,435	1,278,626	4,849,323
2008	1,105,426	1,195,215	1,211,982	1,186,806	4,699,428
2007	891,761	949,556	979,602	1,015,033	3,835,952
2006	529,585	659,719	761,099	803,576	2,753,979
Lucentis	Q1	Q2	Q3	Q4	Total
2013	1,203,179	1,171,423	1,200,791	1,212,651	4,788,045
2012	1,079,092	1,086,543	1,097,541	1,109,695	4,372,871
2011	887,757	943,418	1,052,809	1,075,015	3,958,999
2010	721,967	698,890	745,376	804,684	2,970,917
2009	462,103	469,736	555,296	615,212	2,102,347
2008	363,615	393,682	460,167	454,922	1,672,386
2007	224,820	219,579	299,995	322,300	1,066,695
2006	—	—	10,689	157,742	168,431
Xolair	Q1	Q2	Q3	Q4	Total
2013	341,309	365,778	391,900	401,333	1,500,321
2012	310,234	314,638	347,796	340,431	1,313,100
2011	267,754	277,642	310,874	314,911	1,171,182
2010	228,859	225,878	251,055	263,389	969,179
2009	184,669	181,086	211,006	219,693	796,454
2008	137,875	169,521	177,179	183,753	668,329
2007	129,172	130,700	144,250	147,754	551,876
2006	95,241	99,354	112,608	118,002	425,204
Perjeta	Q1	Q2	Q3	Q4	Total
2013	34,008	55,076	66,353	87,949	243,386
2012	—	—	5,080	25,000	30,079
2011	—	—	—	—	—
2010	—	—	—	—	—
2009	—	—	—	—	—
2008	—	—	—	—	—
2007	—	—	—	—	—
2006	—	—	—	—	—
Kadcyla	Q1	Q2	Q3	Q4	Total
2013	—	21,459	73,626	85,906	180,991
2012	—	—	—	—	—
2011	—	—	—	—	—
2010	—	—	—	—	—
2009	—	—	—	—	—
2008	—	—	—	—	—
2007	—	—	—	—	—
2006	—	—	—	—	—
Tysabri	Q1	Q2	Q3	Q4	Total
2013	434,677	451,358	387,407	403,334	1,676,776
2012	374,430	401,743	391,623	408,711	1,576,508
2011	329,696	356,876	388,758	381,618	1,456,948
2010	293,047	287,925	293,664	316,657	1,191,292
2009	221,854	229,993	257,240	285,481	994,569
2008	129,430	163,076	200,783	233,070	726,359
2007	30,468	48,715	71,972	94,521	245,675
2006	—	—	—	7,890	7,890
Actemra	Q1	Q2	Q3	Q4	Total
2013	87,703	91,374	97,961	124,815	401,852
2012	56,662	66,624	71,505	82,053	276,843
2011	30,433	35,370	46,709	48,671	161,183
2010	52,908	5,405	10,493	22,919	91,725
2009	19,504	17,920	30,313	39,888	107,625
2008	1,452	1,377	5,981	12,305	21,115
2007	—	—	—	1,137	1,137
2006	—	—	—	—	—
* As reported to PDL by its licensee. Dates in above charts
reflect when PDL receives royalties on sales. Sales occurred
in the quarter prior to the dates in the above charts.
Totals may not sum due to rounding

Manufacturing Location & Sales - Genentech / Roche & Novartis ($ in 000's) *
Avastin Sales	2012 - Q3		2012 - Q4		2013 - Q1		2013 - Q2		2013 - Q3		2013 - Q4
US Made & Sold	679,914		710,501		664,109		750,491		716,337		765,636
US Made & ex-US Sold	428,976		281,905		161,369		165,651		360,177		349,836
ex-US Made & Sold	442,437		670,572		827,629		778,536		669,621		704,405
Total	1,551,327		1,662,977		1,653,108		1,694,678		1,746,135		1,819,877
US Made & Sold	44	%	43	%	40	%	44	%	41	%	42	%
US Made & ex-US Sold	28	%	17	%	10	%	10	%	21	%	19	%
ex-US Made & Sold	29	%	40	%	50	%	46	%	38	%	39	%
Herceptin Sales	2012 - Q3		2012 - Q4		2013 - Q1		2013 - Q2		2013 - Q3		2013 - Q4
US Made & Sold	503,612		515,790		514,113		583,677		518,790		561,990
US Made & ex-US Sold	545,625		552,127		486,400		563,243		522,159		383,439
ex-US Made & Sold	614,459		582,578		681,060		597,225		640,911		781,123
Total	1,663,695		1,650,495		1,681,574		1,744,145		1,681,860		1,726,551
US Made & Sold	30	%	31	%	31	%	33	%	31	%	33	%
US Made & ex-US Sold	33	%	33	%	29	%	32	%	31	%	22	%
ex-US Made & Sold	37	%	35	%	41	%	34	%	38	%	45	%
Lucentis Sales	2012 - Q3		2012 - Q4		2013 - Q1		2013 - Q2		2013 - Q3		2013 - Q4
US Made & Sold	385,746		381,592		392,207		419,030		449,834		461,380
US Made & ex-US Sold	711,795		728,103		810,972		752,393		750,958		751,271
ex-US Made & Sold	—		—		—		—		—		—
Total	1,097,541		1,109,695		1,203,179		1,171,423		1,200,791		1,212,651
US Made & Sold	35	%	34	%	33	%	36	%	37	%	38	%
US Made & ex-US Sold	65	%	66	%	67	%	64	%	63	%	62	%
ex-US Made & Sold	0	%	0	%	0	%	0	%	0	%	0	%
Xolair Sales	2012 - Q3		2012 - Q4		2013 - Q1		2013 - Q2		2013 - Q3		2013 - Q4
US Made & Sold	211,702		210,892		207,976		218,860		236,180		242,991
US Made & ex-US Sold	—		—		—		—		—		—
ex-US Made & Sold	136,094		129,540		133,333		146,918		155,720		158,342
Total	347,796		340,431		341,309		365,778		391,900		401,333
US Made & Sold	61	%	62	%	61	%	60	%	60	%	61	%
US Made & ex-US Sold	0	%	0	%	0	%	0	%	0	%	0	%
ex-US Made & Sold	39	%	38	%	39	%	40	%	40	%	39	%
Perjeta Sales	2012 - Q3		2012 - Q4		2013 - Q1		2013 - Q2		2013 - Q3		2013 - Q4
US Made & Sold	5,080		24,571		32,377		48,979		49,111		54,168
US Made & ex-US Sold	—		428		1,632		6,096		17,242		33,781
ex-US Made & Sold	—		—		—		—		—		—
Total	5,080		25,000		34,008		55,076		66,353		87,949
US Made & Sold	100	%	98	%	95	%	89	%	74	%	62	%
US Made & ex-US Sold	0	%	2	%	5	%	11	%	26	%	38	%
ex-US Made & Sold	0	%	0	%	0	%	0	%	0	%	0	%
Kadcyla Sales	2012 - Q3		2012 - Q4		2013 - Q1		2013 - Q2		2013 - Q3		2013 - Q4
US Made & Sold	—		—		—		21,459		72,887		82,395
US Made & ex-US Sold	—		—		—		—		739		3,510
ex-US Made & Sold	—		—		—		—		—		—
Total	—		—		—		21,459		73,626		85,906
US Made & Sold	0	%	0	%	0	%	100	%	99	%	96	%
US Made & ex-US Sold	0	%	0	%	0	%	0	%	1	%	4	%
ex-US Made & Sold	0	%	0	%	0	%	0	%	0	%	0	%
Total Sales	2012 - Q3		2012 - Q4		2013 - Q1		2013 - Q2		2013 - Q3		2013 - Q4
US Made & Sold	1,786,053		1,843,345		1,810,783		2,042,496		2,043,139		2,168,559
US Made & ex-US Sold	1,686,395		1,562,564		1,460,373		1,487,383		1,651,276		1,521,837
ex-US Made & Sold	1,192,990		1,382,690		1,642,023		1,522,679		1,466,252		1,643,870
Total	4,665,438		4,788,598		4,913,178		5,052,559		5,160,667		5,334,267
US Made & Sold	38	%	38	%	37	%	40	%	40	%	41	%
US Made & ex-US Sold	36	%	33	%	30	%	29	%	32	%	29	%
ex-US Made & Sold	26	%	29	%	33	%	30	%	28	%	31	%
* As reported to PDL by its licensee. Dates in above charts
reflect when PDL receives royalties on sales. Sales occurred
in the quarter prior to the dates in the above charts.
Totals may not sum due to rounding